EMA/FDA - Joint Q&A on quality development and good manufacturing practice for Priority Medicines (PRIME) and Breakthrough therapy (BT) designation applications

20th December 2023

EMA/FDA

EMA and the FDA have just published a joint Q&A document on quality development and good manufacturing practice for Priority Medicines (PRIME) and Breakthrough therapy (BT) designation applications

View Now

Back to News Archive